Compare LAKE & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAKE | ACOG |
|---|---|---|
| Founded | 1982 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 130.9M |
| IPO Year | 1986 | N/A |
| Metric | LAKE | ACOG |
|---|---|---|
| Price | $15.09 | $5.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $25.00 | $18.00 |
| AVG Volume (30 Days) | 94.2K | ★ 98.7K |
| Earning Date | 12-09-2025 | 11-13-2025 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $191,631,000.00 | $7,427,199.00 |
| Revenue This Year | $29.73 | N/A |
| Revenue Next Year | $8.45 | $101.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.13 | N/A |
| 52 Week Low | $12.76 | $3.75 |
| 52 Week High | $27.28 | $11.54 |
| Indicator | LAKE | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 39.60 |
| Support Level | $13.51 | $5.66 |
| Resistance Level | $15.24 | $6.18 |
| Average True Range (ATR) | 0.62 | 0.45 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 46.47 | 22.68 |
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.